|
1
|
Sato Y, Yoshizato T, Shiraishi Y, Maekawa
S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki
H, et al: Integrated molecular analysis of clear-cell renal cell
carcinoma. Nat Genet. 45:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koul H, Huh JS, Rove KO, Crompton L, Koul
S, Meacham RB and Kim FJ: Molecular aspects of renal cell
carcinoma: a review. Am J Cancer Res. 1:240–254. 2011.PubMed/NCBI
|
|
3
|
Lin JA, Fang SU, Su CL, Hsiao CJ, Chang
CC, Lin YF and Cheng CW: Silencing glucose-regulated protein 78
induced renal cell carcinoma cell line G1 cell-cycle arrest and
resistance to conventional chemotherapy. Urol Oncol. 32:29.e1–11.
2014. View Article : Google Scholar
|
|
4
|
Molina AM, Tickoo SK, Ishill N, Trinos MJ,
Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P and Motzer RJ:
Sarcomatoid-variant renal cell carcinoma: treatment outcome and
survival in advanced disease. Am J Clin Oncol. 34:454–459. 2011.
View Article : Google Scholar
|
|
5
|
Cho IC and Chung J: Current status of
targeted therapy for advanced renal cell carcinoma. Korean J Urol.
53:217–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang X, Wang W, Mize GJ, Takayama TK,
True LD and Vessella RL: Protease-activated receptor 2 signaling
upregulates angiogenic growth factors in renal cell carcinoma. Exp
Mol Pathol. 94:91–97. 2013. View Article : Google Scholar
|
|
7
|
Chen Y, Dawes PT and Mattey DL:
Polymorphism in the vascular endothelial growth factor A (VEGFA)
gene is associated with serum VEGF-A level and disease activity in
rheumatoid arthritis: differential effect of cigarette smoking.
Cytokine. 58:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Larsen AK, Ouaret D, El Ouadrani K and
Petitprez A: Targeting EGFR and VEGF(R) pathway cross-talk in tumor
survival and angiogenesis. Pharmacol Ther. 131:80–90. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi S: Vascular endothelial growth
factor (VEGF), VEGF receptors and their inhibitors for
antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gray RT, O'Donnell ME, Maxwell P, McGuigan
JA and Spence GM: Long-term follow-up of immunocytochemical
analysis of vascular endothelial growth factor (VEGF), and its two
receptors, VEGF-R1 (Flt-1) and VEGF-R2 (Flk-1/KDR), in
oesophagogastric cancer. Int J Biol Markers. 28:63–70. 2013.
View Article : Google Scholar
|
|
11
|
Wang L, Rahman S, Lin CY, Valdivia J, Than
K, La Marca F and Park P: A novel murine model of human renal cell
carcinoma spinal metastasis. J Clin Neurosci. 19:881–883. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Albiges L, Salem M, Rini B and Escudier B:
Vascular endothelial growth factor-targeted therapies in advanced
renal cell carcinoma. Hematol Oncol Clin North Am. 25:813–833.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Castel SE and Martienssen RA: RNA
interference in the nucleus: roles for small RNAs in transcription,
epigenetics and beyond. Nat Rev Genet. 14:100–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sliva K and Schnierle BS: Selective gene
silencing by viral delivery of short hairpin RNA. Virol J 2010.
7:2482010.
|
|
15
|
Benson DA, Boguski M, Lipman DJ and Ostell
J: GenBank. Nucleic Acids Res. 22:3441–3444. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gerber DE: Targeted therapies: a new
generation of cancer treatments. Am Fam Physician. 77:311–319.
2008.PubMed/NCBI
|
|
18
|
Eichelberg C, Junker K, Ljungberg B and
Moch H: Diagnostic and prognostic molecular markers for renal cell
carcinoma: a critical appraisal of the current state of research
and clinical applicability. Eur Urol. 55:851–863. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ellis LM and Hicklin DJ: VEGF-targeted
therapy: mechanisms of anti-tumour activity. Nat Rev Cancer.
8:579–591. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lane HA, Wood JM, McSheehy PM, Allegrini
PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM,
Martiny-Baron G, Schnell CR, et al: mTOR inhibitor RAD001
(everolimus) has antiangiogenic/vascular properties distinct from a
VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 15:1612–1622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Welti J, Loges S, Dimmeler S and Carmeliet
P: Recent molecular discoveries in angiogenesis and antiangiogenic
therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Conley SJ, Gheordunescu E, Kakarala P,
Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS:
Antiangiogenic agents increase breast cancer stem cells via the
generation of tumor hypoxia. Proc Natl Acad Sci USA. 109:2784–2789.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gandellini P, Profumo V, Folini M and
Zaffaroni N: MicroRNAs as new therapeutic targets and tools in
cancer. Expert Opin Ther Targets. 15:265–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wannenes F, Ciafré SA, Niola F, Frajese G
and Farace MG: Vector-based RNA interference against vascular
endothelial growth factor-A significantly limits vascularization
and growth of prostate cancer in vivo. Cancer Gene Ther.
12:926–934. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Filleur S, Courtin A, Ait-Si-Ali S,
Guglielmi J, Merle C, Harel-Bellan A, Clézardin P and Cabon F:
SiRNA-mediated inhibition of vascular endothelial growth factor
severely limits tumor resistance to antiangiogenic thrombospondin-1
and slows tumor vascularization and growth. Cancer Res.
63:3919–3922. 2003.PubMed/NCBI
|
